Company intelligence / Profile preview

Retinal Research Institute

Phoenix, Arizona, United States

Ownership: Private
Development stage: Other

Overview

The Institute is a large clinical trial site participating in national and international multicenter trials of advanced retinal therapies, involved in pivotal trials supporting approval of new drugs (such as for macular degeneration and diabetic eye diseases), but does not develop proprietary compounds itself. Clinical results refer to external sponsors' programs.

Therapeutic areas: Ophthalmology
Modalities: BiologicSmall moleculeDeviceGene therapy
Industry: Contract Research Organization

Partnerships

GenentechAviceda TherapeuticsAnnexon BiosciencesAstellasEyebioKodiak BiosciencesOptheaAsclepix TherapeuticsEyePoint PharmaceuticalsAldeyra Therapeutics

Beyond the preview

Go deeper on Retinal Research Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Retinal Research Institute.

Explore the full profile